Table S3 from ASS1-Mediated Reductive Carboxylation of Cytosolic Glutamine Confers Ferroptosis Resistance in Cancer Cells

Table S3 from ASS1-Mediated Reductive Carboxylation of Cytosolic Glutamine Confers Ferroptosis Resistance in Cancer Cells

<p>Supplementary RNA sequencing raw data</p>

Uloženo v:

Podrobná bibliografie
Hlavní autor:	Qiangsheng Hu (15400215) (author)
Další autoři:	Jie Dai (15400218) (author), Zheng Zhang (15400221) (author), Huansha Yu (15400224) (author), Jing Zhang (15400227) (author), Xinsheng Zhu (15400230) (author), Yi Qin (15400233) (author), Lele Zhang (15400236) (author), Peng Zhang (8812895) (author)
Vydáno:	2025
Témata:	Cancer Cancer Biology Molecular and Cellular Biology Cell Death and Senescence Ferroptosis Lung Cancer Metabolism Metabolomics Oncogenes & Tumor Suppressors Oncogenes
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky

Table S2 from ASS1-Mediated Reductive Carboxylation of Cytosolic Glutamine Confers Ferroptosis Resistance in Cancer Cells
Autor: Qiangsheng Hu (15400215)
Vydáno: (2025)

Table S2 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
Autor: Cheng-Kai Wang (14963880)
Vydáno: (2025)

Figure S1A-B from Empty Spiracles Homeobox 2 Transcription Factor Functions as a Tumor Suppressor in Renal Cell Carcinoma by Targeting CADM1
Autor: Zhibin Fu (21644135)
Vydáno: (2025)

Figure S1C from Empty Spiracles Homeobox 2 Transcription Factor Functions as a Tumor Suppressor in Renal Cell Carcinoma by Targeting CADM1
Autor: Zhibin Fu (21644135)
Vydáno: (2025)

Figure S2 from Empty Spiracles Homeobox 2 Transcription Factor Functions as a Tumor Suppressor in Renal Cell Carcinoma by Targeting CADM1
Autor: Zhibin Fu (21644135)
Vydáno: (2025)

Figure S3 from Empty Spiracles Homeobox 2 Transcription Factor Functions as a Tumor Suppressor in Renal Cell Carcinoma by Targeting CADM1
Autor: Zhibin Fu (21644135)
Vydáno: (2025)

Figure S4 from Empty Spiracles Homeobox 2 Transcription Factor Functions as a Tumor Suppressor in Renal Cell Carcinoma by Targeting CADM1
Autor: Zhibin Fu (21644135)
Vydáno: (2025)

Figure S5 from Empty Spiracles Homeobox 2 Transcription Factor Functions as a Tumor Suppressor in Renal Cell Carcinoma by Targeting CADM1
Autor: Zhibin Fu (21644135)
Vydáno: (2025)

Figure S6 from Empty Spiracles Homeobox 2 Transcription Factor Functions as a Tumor Suppressor in Renal Cell Carcinoma by Targeting CADM1
Autor: Zhibin Fu (21644135)
Vydáno: (2025)

Figure S7 from Empty Spiracles Homeobox 2 Transcription Factor Functions as a Tumor Suppressor in Renal Cell Carcinoma by Targeting CADM1
Autor: Zhibin Fu (21644135)
Vydáno: (2025)

Figure S8 from Empty Spiracles Homeobox 2 Transcription Factor Functions as a Tumor Suppressor in Renal Cell Carcinoma by Targeting CADM1
Autor: Zhibin Fu (21644135)
Vydáno: (2025)

Supplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Autor: Sebastian Scheich (16509372)
Vydáno: (2025)

Table S1 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
Autor: Giulia Montuori (22375448)
Vydáno: (2025)

Table S2 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
Autor: Giulia Montuori (22375448)
Vydáno: (2025)

Table S3 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
Autor: Giulia Montuori (22375448)
Vydáno: (2025)

Table S4 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
Autor: Giulia Montuori (22375448)
Vydáno: (2025)

Supplementary Figure 1 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
Autor: Francisco Exposito (16721403)
Vydáno: (2025)

Supplementary Figure 2 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
Autor: Francisco Exposito (16721403)
Vydáno: (2025)

Supplementary Figure 3 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
Autor: Francisco Exposito (16721403)
Vydáno: (2025)

Supplementary Figure 4 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
Autor: Francisco Exposito (16721403)
Vydáno: (2025)

Supplementary Figure 5 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
Autor: Francisco Exposito (16721403)
Vydáno: (2025)

Supplementary Table S1 from BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
Autor: Sarah E. Barnett (15100356)
Vydáno: (2025)

Supplementary Table S2 from BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
Autor: Sarah E. Barnett (15100356)
Vydáno: (2025)

Supplementary Table S3 from BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
Autor: Sarah E. Barnett (15100356)
Vydáno: (2025)

Supplementary Table S4 from BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
Autor: Sarah E. Barnett (15100356)
Vydáno: (2025)

Supplementary Table S5 from BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
Autor: Sarah E. Barnett (15100356)
Vydáno: (2025)

Supplementary Data 1 from Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death
Autor: Joshua H. Choe (15306085)
Vydáno: (2025)

Supplementary Data 2 from Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death
Autor: Joshua H. Choe (15306085)
Vydáno: (2025)

Supplementary Data 3 from Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death
Autor: Joshua H. Choe (15306085)
Vydáno: (2025)

Supplementary Data 4 from Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death
Autor: Joshua H. Choe (15306085)
Vydáno: (2025)

Supplementary Data 5 from Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death
Autor: Joshua H. Choe (15306085)
Vydáno: (2025)

Supplementary Data 6 from Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death
Autor: Joshua H. Choe (15306085)
Vydáno: (2025)

Figure 1 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Autor: Christina Esdar (16424072)
Vydáno: (2025)

Figure 2 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Autor: Christina Esdar (16424072)
Vydáno: (2025)

Figure 3 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Autor: Christina Esdar (16424072)
Vydáno: (2025)

Figure 4 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Autor: Christina Esdar (16424072)
Vydáno: (2025)

Figure 5 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Autor: Christina Esdar (16424072)
Vydáno: (2025)

Figure 6 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Autor: Christina Esdar (16424072)
Vydáno: (2025)

Supplementary Table S1 from A Therapeutically Targetable NOTCH1–SIRT1–KAT7 Axis in T-cell Leukemia
Autor: Olga Lancho (15125854)
Vydáno: (2025)

Supplementary Table S2 from A Therapeutically Targetable NOTCH1–SIRT1–KAT7 Axis in T-cell Leukemia
Autor: Olga Lancho (15125854)
Vydáno: (2025)